Key Points
- To evaluate the clinical characteristics, prescribed therapies, and 1-year clinical outcomes in a large representative cohort of Russian outpatients with heart failure.
- Prospective, observational, multicenter registry study (PRIORITY-HF) enrolling outpatients aged 18 years and older with heart failure across 50 regions of the Russian Federation between 2020 and 2022 (N=19,981).
- Patients were categorized by ejection fraction phenotype: reduced (HFrEF, 34.9%), mildly reduced (HFmrEF, 24.7%), and preserved (HFpEF, 40.4%), with follow-up assessing all-cause mortality and heart failure hospitalizations at 12 months.
- Guideline-directed medical therapies were prescribed at varying frequencies (92% renin-angiotensin-aldosterone system inhibitors, 86% beta-blockers, 72% mineralocorticoid receptor antagonists, and 40% SGLT2 inhibitors), with only 46.6% of HFrEF patients receiving complete quadruple therapy.
- At 12 months, all-cause mortality reached 5.2% overall (8.1% for HFrEF, 4.6% for HFmrEF, and 3.1% for HFpEF).
- Cumulative 12-month heart failure-related hospitalization was 6.3% overall, occurring in 10.4% of HFrEF, 6.2% of HFmrEF, and 2.9% of HFpEF patients.
Structured PICO
PPopulation19,981 outpatients diagnosed with heart failure aged 18 years and older in 50 regions of the Russian Federation, mean age 64.9 years, 63.5% men.
OOutcomeAll-cause mortality and cumulative HF-related hospitalization rate at 12 monthshard clinical
In a large Russian registry of outpatients with heart failure, patients were relatively young with a high comorbidity burden and suboptimal use of guideline-directed medical therapy, particularly quadruple therapy in HFrEF, leading to significant differences in 1-year mortality and hospitalization across ejection fraction phenotypes.